Related Experiment Video
Updated: May 2, 2026
07:10
Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
Published on: June 18, 2020
23.0K
Pharmacological prevention of variceal bleeding. New developments
1Department of Medicine, Hospital Clínic i Provincial, University of Barcelona, Spain.
Bailliere'S Clinical Gastroenterology
|June 1, 1997
Summary
Beta-blockers are the primary treatment for preventing esophageal variceal bleeding in cirrhosis patients. Combining beta-blockers with isosorbide-5-mononitrate shows promise for enhanced portal pressure reduction and bleeding prevention.
Area of Science:
- Hepatology
- Gastroenterology
- Pharmacology
Background:
- Portal hypertension is a major complication of cirrhosis.
- Pharmacological therapy, particularly beta-blockers, is crucial for managing portal hypertension and its complications.
- Beta-blockers are the established prophylactic therapy for esophageal variceal bleeding and prevent rebleeding.
Purpose of the Study:
- To evaluate the efficacy of pharmacological agents in reducing portal hypertension.
- To explore new therapeutic approaches for preventing variceal bleeding.
- To assess the potential of combined beta-blocker and isosorbide-5-mononitrate therapy.
Main Methods:
- Review of existing evidence on pharmacological treatments for portal hypertension.
- Analysis of the effectiveness of beta-blockers in reducing portal pressure gradient.
- Investigation of combined beta-blocker and isosorbide-5-mononitrate administration.
Main Results:
- Beta-blockers are the most evidence-based drugs for reducing portal hypertension.
- A portal pressure gradient below 12 mmHg or a >20% reduction is linked to near-complete protection from esophageal bleeding.
- Combined therapy with beta-blockers and isosorbide-5-mononitrate demonstrates potentiated portal pressure reduction and high efficacy in trials.
Conclusions:
- Beta-blockers are essential for managing portal hypertension complications, especially variceal bleeding.
- Achieving significant portal pressure reduction with beta-blockers alone is challenging for some patients.
- Combined beta-blocker and isosorbide-5-mononitrate therapy represents a promising strategy for improved outcomes in portal hypertension management.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:24Esophageal Varices-I: Introduction
2.4K
Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
2.4K
01:28Esophageal Varices-II: Clinical Features and Management
884
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
884
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
319
Varicose veins, or varicosities, develop when the valves in the veins, which control blood flow, weaken or damage. It causes blood to pool and the veins to enlarge. Understanding the clinical manifestations, diagnostic approaches, and management options for varicose veins is crucial for effective treatment and relief.Clinical manifestationsClinical manifestations of varicose veins include a heavy, achy feeling or pain after prolonged standing or sitting. This discomfort can often be relieved by...
319
01:29Venous Thrombosis III: Interprofessional Care
482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482